btk degrader abbv-101
Generic: BTK Degrader ABBV-101
btk degrader abbv-101: 1 clinical trial tracked.
btk degrader abbv-101 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about btk degrader abbv-101, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies
Primary endpoint: Number of Participants with Adverse Events (AE)
InterventionalRandomizedopen135 enrolledStarted 2023-06Completion 2031-0350 sites · Canada, France, Germany, Israel…AbbVie